Q4 2025 Indoco Remedies Ltd Earnings Call Transcript
Key Points
- Indoco Remedies Ltd (BOM:532612) has successfully launched its OTC subsidiary, Warren Remedies Private Limited, which has shown promising growth in tertiary demand.
- The company's star product, Cylopam, has added INR25 crores incrementally in one year, reaching a turnover of INR178 crores.
- The European Medicine Agency audit of Plant 2 in Goa was successful with no critical or major findings, indicating progress in compliance.
- Positive communication from the US FDA allows the restart of a couple of lines in Plant 2, potentially boosting international sales.
- The company is implementing a master manufacturing plan to increase efficiency, reduce costs, and improve manufacturing processes across its sites.
- Indoco Remedies Ltd (BOM:532612) faced a significant decline in revenues due to planned shutdowns and a warning letter from the US FDA affecting its sterile plant in Goa.
- The company's consolidated EBITDA to net sales for the quarter was negative, indicating financial strain.
- The international business, particularly in the US and Europe, saw a substantial drop in revenues due to supply chain disruptions and regulatory issues.
- High investment costs in Warren Remedies and ongoing remediation expenses have impacted the company's margins.
- The company's debt levels have increased significantly, with total outstanding debt nearing INR960 crores, putting pressure on financial stability.
Ladies and gentlemen, good day, and welcome to Indoco Remedies Limited Q4 and FY25 Earnings Conference Call hosted by Dolat Capital. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. Rashmi Shetty from Dolat Capital. Thank you, and over to you, ma'am.
Thank you, Manav, and good afternoon, everyone. I, Rashmi Shetty, on behalf of Dolat Capital, welcome you to the Q4 FY25 earnings call of Indoco Remedies. We thank the Indoco Remedies' management for giving us this opportunity to host the call. Today, we have with us the senior management of the company represented by Ms. Aditi Kare Panandikar, Managing Director; Sundeep Bambolkar, Joint Managing Director; and Pramod Gorpade, CFO.
I will now hand over the call to the management for the opening remarks. Over to you, sir.
Thank you, Rashmi. Good
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
